Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.

[1]  Yair Lotan,et al.  Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy , 2008, Cancer.

[2]  Y. Lotan,et al.  Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness , 2007, Modern Pathology.

[3]  Y. Lotan,et al.  Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. , 2007, The Journal of urology.

[4]  C. Roehrborn,et al.  Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. , 2007, The Lancet. Oncology.

[5]  Y. Lotan,et al.  Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. , 2006, Cancer.

[6]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.

[7]  Y. Lotan,et al.  Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.

[8]  Y. Lotan,et al.  Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. , 2006, Human pathology.

[9]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[10]  N. Malats,et al.  The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors , 2006, Clinical Cancer Research.

[11]  S. Groshen,et al.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Shariat,et al.  Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. , 2003, Urology.

[14]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Deppert,et al.  Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals , 2003, Oncogene.

[16]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[18]  T. Wheeler,et al.  Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. , 2000, Urology.

[19]  A. Cittadini,et al.  Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. Korkolopoulou,et al.  Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. , 2000, Human pathology.

[21]  L. Wiesmüller,et al.  Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53 , 1999, Oncogene.

[22]  A. Zlotta,et al.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. , 1999, The Journal of urology.

[23]  S. Groshen,et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. , 1998, Journal of the National Cancer Institute.

[24]  C. Dinney,et al.  p53 and RB expression predict progression in T1 bladder cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[26]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[27]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[28]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[29]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[30]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.